T2 Biosystems (NASDAQ:TTOO) PT Lowered to $3.00

T2 Biosystems (NASDAQ:TTOO) had its target price cut by Canaccord Genuity Group from $12.00 to $3.00 in a report released on Monday, Benzinga reports. They currently have a hold rating on the medical equipment provider’s stock.

T2 Biosystems Trading Up 3.5 %

Shares of NASDAQ TTOO opened at $2.94 on Monday. The business has a 50 day simple moving average of $3.76 and a 200-day simple moving average of $10.22. T2 Biosystems has a twelve month low of $2.60 and a twelve month high of $70.00.

Institutional Trading of T2 Biosystems

A hedge fund recently bought a new stake in T2 Biosystems stock. Banco Santander S.A. bought a new position in T2 Biosystems, Inc. (NASDAQ:TTOO) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 189,134 shares of the medical equipment provider’s stock, valued at approximately $42,000. Banco Santander S.A. owned 5.66% of T2 Biosystems at the end of the most recent reporting period. 23.18% of the stock is currently owned by hedge funds and other institutional investors.

T2 Biosystems Company Profile

T2 Biosystems, Inc, an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. Its technology enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, cerebral spinal fluid, and urine.